Calcified Tissue International

, Volume 81, Issue 2, pp 139–144

Selective Estrogen Receptor Modulator Inhibits Osteocyte Apoptosis during Abrupt Estrogen Withdrawal: Implications for Bone Quality Maintenance

  • C. Huber
  • S. Collishaw
  • J. R. Mosley
  • J. Reeve
  • B. S. Noble
Article

Abstract

Estrogens exert positive effects on the quantity and quality of bone, including the maintenance of osteocytes through the inhibition of their apoptosis. Ideally, selective estrogen receptor modulators (SERMs) confer all of the positive bone-associated effects of estrogens without any adverse effects. In a similar way to estrogen, the raloxifene analog LY 117018 has been shown to prevent bone loss in ovariectomized (OVX) rats. In this study, we investigated whether the osteocyte-sparing effect of 17β-estradiol can be mimicked by the SERM LY 117018 in a rat model of OVX. Twenty-four juvenile female rats were divided into four treatment groups: sham-operated (SHAM), OVX, OVX + 17β-estradiol (OVX+E2), and OVX + LY 117018 (OVX+SERM). At 7 or 14 days following the start of treatment, the radius and ulna were removed. The percentage of apoptotic osteocytes, determined using an in situ nick-translation method, was increased (2.5–fold at 7 days and sixfold at 14 days) in the OVX group compared with SHAM in both the radius and ulna. Treatment of OVX animals with either 17β-estradiol at a dose rate of 0.125 mg/kg/day or LY 117018 at a dose rate of 3 mg/kg/day prevented these increases in osteocyte apoptosis similarly. These observations demonstrate that LY 117018 exerts a powerful inhibitory effect upon osteocyte apoptosis directly after estrogen loss, in a similar way to the known effect of 17β-estradiol replacement. These results point to the potential benefits of SERMs on both the quantity and quality of bone in E2-depleted rats.

Keywords

Osteocyte Apoptosis 17β-Estradiol Selective estrogen receptor modulator 

References

  1. 1.
    Lanyon LE (1993) Osteocytes, strain detection, bone modeling and remodeling. Calcif Tissue Int 53(suppl 1):S102–S107PubMedCrossRefGoogle Scholar
  2. 2.
    Kamijou T, Nakajima T, Ozawa H (1994) Effects of osteocytes on osteoinduction in the autogenous rib graft in the rat mandible. Bone 15:629–637PubMedCrossRefGoogle Scholar
  3. 3.
    Marrotti G, Remaggi F, Tartari F (1998) Morphometric investigation on osteocytes on human auditory ossicles. Ann Anat 180:449–453Google Scholar
  4. 4.
    Power J, Noble BS, Loveridge N, Bell KL, Rushton N, Reeve J (2001) Osteocyte lacunar occupancy in the femoral neck cortex: an association with cortical remodelling in hip fracture case and controls. Calcif Tissue Int 69:13–19PubMedCrossRefGoogle Scholar
  5. 5.
    Qiu S, Rao DS, Palnitkar S, Parfitt AM (2002) Relationship between osteocyte density and bone formation rate in human cancellous bone. Bone 31:709–711PubMedCrossRefGoogle Scholar
  6. 6.
    Hernandez CJ, Majeska RJ, Schaffler MB (2004) Osteocyte density in woven bone. Bone 35:1095–1099PubMedCrossRefGoogle Scholar
  7. 7.
    Burr DB, Martin RB, Schaffler MB, Radin EL (1985) Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18:189–200PubMedCrossRefGoogle Scholar
  8. 8.
    Parfitt AM (2001) The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res 16:1583–1585PubMedCrossRefGoogle Scholar
  9. 9.
    Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, Reeve J, Skerry TM, Lanyon LE (2003) Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 284:C934–C943PubMedGoogle Scholar
  10. 10.
    Allbright F, Smith PH, Richardson AM (1941) Postmenopausal osteoporosis. JAMA 116:2465–2474Google Scholar
  11. 11.
    Wronski TJ, Dann LM, Scott KS, Cintron M (1989) Long term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45:360–366PubMedCrossRefGoogle Scholar
  12. 12.
    Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175–191PubMedCrossRefGoogle Scholar
  13. 13.
    Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS (1998) The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 13:1243–1250PubMedCrossRefGoogle Scholar
  14. 14.
    Tomkinson A, Reeve J, Shaw RW, Noble BS (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128–3135PubMedCrossRefGoogle Scholar
  15. 15.
    Kauffman RF, Bryant HU (1995) Effective therapeutic management of the postmenopausal state will be a cornerstone in strategies for preserving or improving women’s health in the 21st century. Selective estrogen receptor modulators. Drug News Perspect 8:531–539Google Scholar
  16. 16.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647PubMedCrossRefGoogle Scholar
  17. 17.
    Curiel MD, Calero JA, Guerrero R, Gala J, Gazapo R, de la Piedra C (1998) Effects of LY-117018 HCl on bone remodeling and mineral density in the oophorectomized rat. Am J Obstet Gynecol 178:320–325PubMedCrossRefGoogle Scholar
  18. 18.
    Li X, Takahashi M, Kushida K, Inoue T (1998) The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats. J Bone Miner Res 13:1005–1010PubMedCrossRefGoogle Scholar
  19. 19.
    Hodsman AB, Drost D, Fraher LJ, Holdsworth D, Thornton M, Hock J, Bryant H, Watson PH (1999) The addition of a raloxifene analog (LY117018) allows for reduced PTH(1–34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res 14:675–679PubMedCrossRefGoogle Scholar
  20. 20.
    Bowman AR, Sass DA, Marshall I, Ma YF, Liang H, Jee WS, Epstein S (1996) Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats. J Bone Miner Res 11:1191–1198PubMedCrossRefGoogle Scholar
  21. 21.
    Noble BS, Stevens H, Loveridge N, Reeve J (1997) Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 20:273–282PubMedCrossRefGoogle Scholar
  22. 22.
    Noble BS, Stevens HY (2003) Techniques for the study of apoptosis in bone. In: Helfrich MH, Ralston SH (eds), Methods in Molecular Medicine: Bone Research Protocols. Humana Press, Totowa, NJ, pp 225–236CrossRefGoogle Scholar
  23. 23.
    Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843–846PubMedCrossRefGoogle Scholar
  24. 24.
    Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730PubMedGoogle Scholar
  25. 25.
    Mann V, Huber C, Kogianni G, Collins F, Noble BS (2007) The antioxidant effect of estrogen and SERMs in the inhibition of osteocyte apoptosis in vitro. Bone 40:674–684PubMedCrossRefGoogle Scholar
  26. 26.
    Poole KE, Van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SC, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • C. Huber
    • 1
  • S. Collishaw
    • 1
  • J. R. Mosley
    • 1
  • J. Reeve
    • 2
  • B. S. Noble
    • 1
  1. 1.Musculoskeletal Tissue Engineering Collaboration, Department of MedicineUniversity of EdinburghEdinburghUK
  2. 2.Bone Research Division, University Department of MedicineUniversity of CambridgeCambridgeUK

Personalised recommendations